Skip to main content
Premium Trial:

Request an Annual Quote

Agendia Registers MammaPrint Microarray Test With Dutch Gov t

NEW YORK, Nov. 1 (GenomeWeb News) - Agendia has registered its MammaPrint microarray test as a medical device with the Dutch Healthcare Inspectorate, the company said today. Both the microarray and the array production were registered.


Agendia said the registration complies with Dutch law on medical devices and enables MammaPrint to bear the CE mark. Agendia recently received accreditation for MammaPrint.


The MammaPrint gene-expression service assesses the risk of metastasis in breast cancer patients with a 70-gene profile.


The Amsterdam, Netherlands-based company will also register its other genetic profile-based tests, such as CupPrint, a test for cancer of unknown primary patients.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.